Literature DB >> 28527392

Immune-related bone marrow failure following anti-PD1 therapy.

Jean-Marie Michot1, Jacques Vargaftig2, Charlotte Leduc3, Gilles Quere4, Barbara Burroni5, Julien Lazarovici6, Stéphane Champiat7, Vincent Ribrag6, Olivier Lambotte8.   

Abstract

Entities:  

Keywords:  Anti-PD1 therapy; Aplastic anaemia; Bone marrow failure; Emergent adverse event; Immune-related adverse event

Mesh：

Substances：

Year:  2017        PMID： 28527392     DOI： 10.1016/j.ejca.2017.04.004

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  8 in total

Review 1.  Toxicity of tumor immune checkpoint inhibitors-more attention should be paid.

Authors:  Yu Liu; Hao Wang; Juan Deng; Chenglong Sun; Yayi He; Caicun Zhou
Journal:  Transl Lung Cancer Res       Date:  2019-12

2.  PD-1 deficiency augments bone marrow failure in a minor-histocompatibility antigen mismatch lymphocyte infusion model.

Authors:  Maile K Hollinger; Valentina Giudice; Nicole A Cummings; Guillermo Rivell; Hansheng Zhang; Sachiko Kajigaya; Keyvan Keyvanfar; Jichun Chen; Xingmin Feng; Neal S Young
Journal:  Exp Hematol       Date:  2018-03-07       Impact factor: 3.084

Review 3.  Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.

Authors:  Iosune Baraibar; Ignacio Melero; Mariano Ponz-Sarvise; Eduardo Castanon
Journal:  Drug Saf       Date:  2019-02       Impact factor: 5.606

4.  Pancytopenia And Limbic Encephalopathy Complicating Immunotherapy For Clear Cell Endometrial Cancer With Microsatellite Instability-High (MSI-H).

Authors:  Aladdin Kanbour; Kakil Ibrahim Rasul; Salha Bujassoum Albader; Reem Jawad Al Sulaiman; Gayan Melikyan; Hanan Farghaly; Zsolt Lengyel; Yousef Al Rimawi; Dina Soliman; Nabil Elhadi Omar
Journal:  Onco Targets Ther       Date:  2019-11-19       Impact factor: 4.147

5.  Toxicities associated with checkpoint inhibitors-an overview.

Authors:  Laura Spiers; Nicholas Coupe; Miranda Payne
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

Review 6.  Treatment of patients with cancer using PD‑1/PD‑L1 antibodies: Adverse effects and management strategies (Review).

Authors:  Guangshun Sun; Hanyuan Liu; Xuesong Shi; Pengyu Tan; Weiwei Tang; Xin Chen; Guoqiang Sun; Weijun Yang; Xiangyi Kong; Zhiying Zheng; Hongyong Cao; Guoqiang Shao
Journal:  Int J Oncol       Date:  2022-04-29       Impact factor: 5.884

7.  Pembrolizumab-induced pancytopenia in a patient with squamous cell lung cancer.

Authors:  Yuriko Ueki; Manabu Suzuki; Yuriko Horikawa; Hiromu Watanabe; Yoh Yamaguchi; Chie Morita; Akinari Tsukada; Hiroshi Takumida; Yusaku Kusaba; Takashi Katsuno; Yoshie Tsujimoto; Keita Sakamoto; Masao Hashimoto; Junko Terada; Satoru Ishii; Jin Takasaki; Go Naka; Motoyasu Iikura; Shinyu Izumi; Yuichiro Takeda; Masayuki Hojo; Haruhito Sugiyama
Journal:  Thorac Cancer       Date:  2020-08-07       Impact factor: 3.500

8.  Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review.

Authors:  Nabil E Omar; Kareem A El-Fass; Abdelrahman I Abushouk; Noha Elbaghdady; Abd Elmonem M Barakat; Ahmed E Noreldin; Dina Johar; Mohamed Yassin; Anas Hamad; Shereen Elazzazy; Said Dermime
Journal:  Front Immunol       Date:  2020-10-21       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.